Harnessing the power of proteins to create the next generation of medicines and treatments
Until now, human beings have been unable to design new proteins. The Institute for Protein Design will lead the protein design revolution, becoming the “Bell Labs” of the field and taking on five grand challenges that could change how drugs, vaccines and materials are made.
Paragraph introducing any relevant stats.
Proteins are the molecular machines that make all living things hum. They stop deadly infections, heal cells, capture energy from the sun and so much more. Proteins are built by stringing together chemical building blocks called amino acids, according to instructions in an organism’s genome. These strings then ‘fold up,’ based on the chemical forces between the amino acids, forming the complex three-dimensional structures needed to perform specific jobs. Although nature has been building proteins for more than three billion years, the number of possible proteins is astronomical: there are more ways of assembling 100 amino acids than there are atoms in the universe. For years, scientists have tried to predict the shapes protein molecules should assume based on their amino acids — with limited success. This is known as the “protein folding problem.” Because of its elusive nature, understanding how to harness the power of proteins to solve problems has remained a mystery.
Over the past 20 years, David Baker’s research team has studied the rules of protein folding and encoded them in Rosetta, a computer simulation that’s driven breakthroughs in understanding how proteins form their structure. Now, thanks to the technological convergence of Rosetta, the rise of inexpensive computing and the genomic revolution in reading and writing DNA, for the first time in human history, researchers at the University of Washington School of Medicine’s Institute for Protein Design (IPD) can design new proteins from scratch with functions never before seen in nature. With investment from The Audacious Project, the IPD will expand its ability to design new proteins and venture to fundamentally change how drugs, vaccines, fuels and new materials are made.
The core of this plan is to make IPD the “Bell Labs of Protein Design.” During its heyday in the 1950s, Bell Labs drove the innovations that laid the foundations of the modern digital era.The collaborative environment of Bell Labs attracted top research talent and made it it a hotbed of scientific discovery and technological achievement. Just as Bell Labs helped create the digital revolution, the Institute for Protein Design will work to fuel the protein design revolution. By expanding the Institute, doubling its faculty and training a new generation of scientists, IPD will accelerate the pace of discovery and dissemination of new protein technology. Their work will focus on five Grand Challenges: (1) universal vaccines for flu, HIV and cancer, (2) advanced medications for chronic pain and neurodegenerative diseases, (3) protein nano-containers to bring medicines to specific cells, (4) smart protein therapeutics that can recognize cancerous or otherwise unhealthy cells, and (5) next-generation nanoengineering for solar energy capture and storage.
Why will this succeed?
Located on the University of Washington’s Seattle campus, the IPD and its trainees lead the field of computational protein design. The IPD has already created synthetic proteins that bind viruses and protect against infection. They have pioneered protein-based containers that package and deliver genetic instructions into cells. This advance indicates great potential for smart protein therapeutics. Recent success with new, better flu vaccines that program the immune system to fight multiple strains of the virus pave the way for universal vaccine opportunities. Additionally, the IPD already has experience bringing their discoveries to market, spinning off five new biotech companies in four years.
IPD develops synthetic proteins that can bind viruses and protect against infection. Contribute $25 to test 25 new disease-fighting designs.
Share this talk to show others the incredible potential of new proteins.